"Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome." by Shone O. Almeida

Article

Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome.

Journal of Cardiovascular Computed Tomography (2020)

Shone O. Almeida, Los Angeles Biomedical Research Institute
Reuben J. Ram, University of California, Los Angeles
April Kinninger, Los Angeles Biomedical Research Institute
Matthew J. Budoff, Los Angeles Biomedical Research Institute

Link

Disciplines

Medicine and Health Sciences,
Cardiology and
Internal Medicine

Publication Date

January 17, 2020

DOI

10.1016/J.JCCT.2019.12.033

Citation Information

Shone O. Almeida, Reuben J. Ram, April Kinninger and Matthew J. Budoff. "Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome." Journal of Cardiovascular Computed Tomography Vol. 14 Iss. 4 (2020) p. 343 - 348
Available at: http://works.bepress.com/shone-almeida/9/